PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse‐Type Tenosynovial Giant Cell Tumor

Targeted biological therapies may achieve maximal therapeutic efficacy at doses below the maximum tolerated dose (MTD); therefore, the search for the MTD in clinical studies may not be ideal for these agents. Emactuzumab is an investigational monoclonal antibody that binds to and inhibits the activa...

Descripción completa

Detalles Bibliográficos
Autores principales: Smart, Kevin, Bröske, Ann‐Marie, Rüttinger, Dominik, Mueller, Claudia, Phipps, Alex, Walz, Antje‐Christine, Ries, Carola, Baehner, Monika, Cannarile, Michael, Meneses‐Lorente, Georgina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589268/
https://www.ncbi.nlm.nih.gov/pubmed/32575160
http://dx.doi.org/10.1002/cpt.1964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589268/
https://www.ncbi.nlm.nih.gov/pubmed/32575160
http://dx.doi.org/10.1002/cpt.1964

Ejemplares similares